Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33618971

about

Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy Current knowledge and future research directions in treatment-related second primary malignancies.Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors Subsequent malignant neoplasms after hematopoietic cell transplantation.MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.Therapy-related myeloid leukemia.Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair.Persistent genomic instability in peripheral blood lymphocytes from Hodgkin lymphoma survivors.Hematologic adverse events associated with temozolomide.Pooling-analysis on hMLH1 polymorphisms and cancer risk: evidence based on 31,484 cancer cases and 45,494 cancer-free controls.

P2860

Q33725467-1D0ED191-67C0-4739-9B15-B02DABB02E27 Q34316748-10FD1CE6-B97C-4F51-B991-0CD5B9BAB2B3 Q34604460-5423FD51-4FD9-48DC-98C3-7F899965B1F8 Q35117677-E0271054-7C14-4265-A01B-20E21A45507F Q35327266-753D5AAF-E7F8-4BCF-81B0-713AF68341C4 Q35678455-47578D35-F14E-4FD3-86F1-5DC64C440288 Q36787577-867A7E93-80D9-4D82-9E18-3939FB98EDB5 Q37009760-F966BFF2-2DFE-45B2-B773-A6DC34C11F07 Q37271829-74D491CC-4901-435D-ACAC-643FA677612C Q37855227-E0243B07-2789-4CB4-A8DD-88EBB34DF521 Q38052129-0FE684D5-0A8C-4A3E-9AEC-00F994685C9D Q39612328-97C799D0-DEF2-49AA-B602-594F21E09426 Q39638456-D52A4516-3110-4020-A98F-620D63269B4E Q43998950-09ABF9F6-CA6C-4923-A0B1-D30A8EB6B251 Q47116638-701E2F62-C679-4894-B2C6-AB46F9B353F8

P2860

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33618971

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@ast

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@en

type

label

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@ast

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@en

prefLabel

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@ast

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

@en

P1433

Q33618971-4AC81564-3038-499F-895D-8624114076C4

P1476

Q33618971-63082923-7004-48C4-9438-3312093B7915

P2093

Q33618971-24A02C34-D0BB-408F-9BAC-D5B721C29B12

Q33618971-3B53A137-C1F0-4B99-B7E2-775A9D566427

Q33618971-473FD7C9-FF5F-4275-9E7C-BBCAA7C7367B

Q33618971-50CD06C6-7664-432C-ABC6-CB417DBF689E

Q33618971-60784ABE-6F48-439E-93E0-527B866D9A6B

Q33618971-67FBC6EC-3526-4B74-B7B2-61A5063317BD

Q33618971-69F7E8AA-FC38-4A8D-B925-B8B4DC12B0FE

Q33618971-71AE2E29-B425-465A-86F3-775E1361B4E7

Q33618971-7787DFB5-9864-4C9A-AB4D-501C2D76682D

Q33618971-7E4DBAA1-43D4-49B4-8891-9F67058FB3BD

P2860

Q33618971-23896754-F3E7-4CE8-9D3F-A634F59CBAFD

Q33618971-51DDD409-D36F-4BE4-8DDC-808C375C8A4A

Q33618971-54704A33-651F-4E86-97A3-0A053E14E65E

Q33618971-5FCE126B-AC31-41A1-B8AA-6F3A76BA9AA9

Q33618971-73DA9835-6A91-4E57-B281-3820D08EFC06

Q33618971-7B37D8A5-0FF7-4BA8-8F72-1F97DAEDECFB

Q33618971-86EEC6F5-7030-418B-B9C2-52F42A8CAC02

Q33618971-982A787A-3223-4844-B032-B8C70FCF376A

Q33618971-B7A6C83C-2431-4226-BB93-6BA4F31FC707

Q33618971-BA49210B-A4EE-4818-927F-C96D42D59806

P304

Q33618971-34EFDCA9-BD0D-4673-8220-BCEB82D6CA6B

P31

Q33618971-8ED3CB4A-5052-4866-9854-94534997E50E

P356

Q33618971-D2A71E23-8D93-48B5-BF41-CCDAC329CD5B

P407

Q33618971-376980DE-1088-4180-9E06-E28BD29E5F41

P433

Q33618971-329A9BE0-63D7-416B-A05E-4BA4BAFE670F

P478

Q33618971-59069F06-C5F3-4E3A-AD40-94AD085BCF07

P50

Q33618971-3781B22F-9964-4AB1-B471-5FD1837F3D57

Q33618971-51BFE767-B557-4376-A7BB-D2E3DCE04C9D

Q33618971-B823D3A7-C9A8-4E08-9E12-808C56FCDB20

Q33618971-C0429CDD-7AC0-4F78-A56D-CAF532876A47

P577

Q33618971-723593D4-29A6-48BF-96C2-214BE662F8B4

P698

Q33618971-6D7D10A5-20E1-483B-B0FD-2DD3D8444F04

P921

Q33618971-F5667C7C-4A89-4DF0-8948-FD8D3053C99D

P932

Q33618971-B3A710FB-2172-4CD1-9923-D169C64C3AB2

P356

JMG.2007.053850

P1433

Journal of Medical Genetics

P1476

Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma

@en

P2093

A G Smith

http://www.w3.org/2001/XMLSchema#string

A J Ashcroft

http://www.w3.org/2001/XMLSchema#string

C F Lynch

http://www.w3.org/2001/XMLSchema#string

D Scott

http://www.w3.org/2001/XMLSchema#string

E Holowaty

http://www.w3.org/2001/XMLSchema#string

E Pukkala

http://www.w3.org/2001/XMLSchema#string

E Willett

http://www.w3.org/2001/XMLSchema#string

G H Jackson

http://www.w3.org/2001/XMLSchema#string

G L Jones

http://www.w3.org/2001/XMLSchema#string

H H Storm

http://www.w3.org/2001/XMLSchema#string

P2860

DNA mismatch repair: functions and mechanisms

Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine.

Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.

Tobacco and the risk of acute leukaemia in adults.

Mismatch repair-dependent iterative excision at irreparable O6-methylguanine lesions in human nuclear extracts.

A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1.

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

P304

142-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JMG.2007.053850

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Bengt Glimelius

Gareth J Morgan

P577

2007-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17959715

http://www.w3.org/2001/XMLSchema#string

P921

P932

4022773

http://www.w3.org/2001/XMLSchema#string